Karen L. Furie

Learn More
Donald Lloyd-Jones, MD, ScM, FAHA; Robert Adams, MD, FAHA; Mercedes Carnethon, PhD, FAHA; Giovanni De Simone, MD; T. Bruce Ferguson, MD; Katherine Flegal, PhD*; Earl Ford, MD, MPH*; Karen Furie, MD; Alan Go, MD; Kurt Greenlund, PhD*; Nancy Haase; Susan Hailpern, DPH; Michael Ho, MD, PhD; Virginia Howard, PhD, FAHA; Brett Kissela, MD; Steven Kittner, MD;(More)
Donald Lloyd-Jones, MD, ScM, FAHA; Robert J. Adams, MD, FAHA; Todd M. Brown, MD; Mercedes Carnethon, PhD, FAHA; Shifan Dai, MD, PhD*; Giovanni De Simone, MD; T. Bruce Ferguson, MD; Earl Ford, MD, MPH*; Karen Furie, MD; Cathleen Gillespie; Alan Go, MD; Kurt Greenlund, PhD*; Nancy Haase; Susan Hailpern, DPH; P. Michael Ho, MD, PhD; Virginia Howard, PhD, FAHA;(More)
The aim of this updated statement is to provide comprehensive and timely evidence-based recommendations on the prevention of ischemic stroke among survivors of ischemic stroke or transient ischemic attack. Evidence-based recommendations are included for the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic(More)
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in humans and is characterized by chaotic electrical activity of the atria. It affects one in ten individuals over the age of 80 years, causes significant morbidity and is an independent predictor of mortality. Recent studies have provided evidence of a genetic contribution to AF.(More)
The aim of this new statement is to provide comprehensive and timely evidence-based recommendations on the prevention of ischemic stroke among survivors of ischemic stroke or transient ischemic attack. Evidence-based recommendations are included for the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic treatments(More)
The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of ischemic stroke or transient ischemic attack. The guideline is addressed to all clinicians who manage secondary prevention for these patients. Evidence-based recommendations are provided for control of(More)
BACKGROUND Despite the use of antiplatelet agents, usually aspirin, in patients who have had an ischemic stroke, there is still a substantial rate of recurrence. Therefore, we investigated whether warfarin, which is effective and superior to aspirin in the prevention of cardiogenic embolism, would also prove superior in the prevention of recurrent ischemic(More)